Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leqembi
Biogen's monoclonal antibody for Alzheimer's disease.
Pharma
Novartis-Argo, Eisai, Henlius—Fierce Pharma Asia
Novartis signed a $5.2 billion siRNA deal with Argo. The FDA approved subcutaneous Leqembi. The Hong Kong exchange censured Henlius and its former CEO.
Angus Liu
Sep 5, 2025 9:00am
Eisai scores FDA nod for subcutaneous Leqembi maintenance dose
Aug 29, 2025 5:55pm
Sanofi, Trump, VC capital crunch—Fierce Pharma Asia
Aug 8, 2025 9:32am
Biogen raises sales outlook as 'new Biogen' shapes up
Jul 31, 2025 11:29am
Pfizer, Alzheimer's blood test, Samsung—Fierce Pharma Asia
May 23, 2025 9:00am
New Alzheimer's test will take time to boost Leqembi: analyst
May 19, 2025 1:52pm
